297 related articles for article (PubMed ID: 34670381)
1. Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection.
Zhou HJ; Wu G; Li JM; Naidoo N; Xie YX; Feng BL; Wang P; Luo JW
Ann Palliat Med; 2021 Oct; 10(10):10313-10326. PubMed ID: 34670381
[TBL] [Abstract][Full Text] [Related]
2. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Poordad F; Felizarta F; Asatryan A; Sulkowski MS; Reindollar RW; Landis CS; Gordon SC; Flamm SL; Fried MW; Bernstein DE; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
Hepatology; 2017 Aug; 66(2):389-397. PubMed ID: 28128852
[TBL] [Abstract][Full Text] [Related]
3. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.
Shin HD; Song IH; Lee SH; Kim HS; Lee TH; Eun HS; Kim SH; Lee BS; Chae HB; Kim SH; Song MJ; Ko SY; Kim SB
Korean J Gastroenterol; 2024 Mar; 83(3):111-118. PubMed ID: 38522854
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
Chiu WN; Hung CH; Lu SN; Chen MY; Tung SY; Wei KL; Lu CK; Chen CH; Hu TH; Hu JH; Chen WM; Chang TS
J Viral Hepat; 2020 Sep; 27(9):866-872. PubMed ID: 32343472
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.
Suleiman AA; Lin CW; Liu W; Eckert D; Mensing S; Burroughs M; Kato K; Chayama K; Kumada H; Oberoi RK
J Clin Pharmacol; 2020 Mar; 60(3):331-339. PubMed ID: 31515816
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Chen JJ; Chiu YC; Lee PL; Tung HD; Chiu HC; Chien SC; Cheng PN
J Formos Med Assoc; 2022 Nov; 121(11):2265-2272. PubMed ID: 35581112
[TBL] [Abstract][Full Text] [Related]
8. Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.
Turnes J; Rincón D; Calleja JL; Delgado MB; Rosales JM; Andrade RJ; Manzano ML; Salmerón FJ; López MA; Calvo M; Gómez J; Molina E; Frias YN; Gálvez-Fernández RM; Vallejo-Senra N; París S; Santos de Lamadrid R; Olveira A
Gastroenterol Hepatol; 2022 May; 45(5):342-349. PubMed ID: 34129903
[TBL] [Abstract][Full Text] [Related]
9. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
Liu CH; Yang SS; Peng CY; Lin WT; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
J Viral Hepat; 2020 Jun; 27(6):568-575. PubMed ID: 31981264
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
Nonomura A; Tamori A; Hai H; Kozuka R; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
Intern Med; 2021 Nov; 60(21):3441-3445. PubMed ID: 34024853
[TBL] [Abstract][Full Text] [Related]
11. Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
Zarębska-Michaluk D; Jaroszewicz J; Pabjan P; Łapiński TW; Mazur W; Krygier R; Dybowska D; Halota W; Pawłowska M; Janczewska E; Buczyńska I; Simon K; Dobracka B; Citko J; Laurans Ł; Tudrujek-Zdunek M; Tomasiewicz K; Piekarska A; Sitko M; Białkowska-Warzecha J; Klapaczyński J; Sobala-Szczygieł B; Horban A; Berak H; Deroń Z; Lorenc B; Socha Ł; Tronina O; Flisiak R
J Gastroenterol Hepatol; 2021 Jul; 36(7):1944-1952. PubMed ID: 33171526
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of Japanese hemophilia patient co-infected with HIV and HCV genotype 4a by glecaprevir/pibrentasvir therapy.
Sato K; Kanayama Y; Yamazaki Y; Tojima H; Suga T; Uehara D; Kakizaki S; Yanagisawa K; Uraoka T; Ohnishi H; Okamoto H
Clin J Gastroenterol; 2021 Dec; 14(6):1725-1732. PubMed ID: 34664197
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
Margusino-Framiñán L; Cid-Silva P; Rotea-Salvo S; Mena-de-Cea Á; Suárez-López F; Vázquez-Rodríguez P; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
Eur J Hosp Pharm; 2020 Mar; 27(e1):e41-e47. PubMed ID: 32296504
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland.
Müllhaupt B; Semela D; Ruckstuhl L; Magenta L; Clerc O; Torgler R; Negro F; Semmo N
Swiss Med Wkly; 2021 Jan; 151():w20399. PubMed ID: 33516161
[TBL] [Abstract][Full Text] [Related]
16. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.
Uemura H; Uchida Y; Kouyama JI; Naiki K; Tsuji S; Sugawara K; Nakao M; Motoya D; Nakayama N; Imai Y; Tomiya T; Mochida S
J Gastroenterol; 2019 May; 54(5):459-470. PubMed ID: 30612205
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.
Zhou HJ; Cao J; Shi H; Naidoo N; Semba S; Wang P; Fan YF; Zhu SC
Front Public Health; 2021; 9():779215. PubMed ID: 34957030
[No Abstract] [Full Text] [Related]
18. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.
Chen WM; Wei KL; Tung SY; Shen CH; Chang TS; Yen CW; Hsieh YY; Chiu WN; Hu JH; Lu SN; Hung CH
J Formos Med Assoc; 2020 Nov; 119(11):1593-1600. PubMed ID: 32839045
[TBL] [Abstract][Full Text] [Related]
19. Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis.
Lu M; Rupp LB; Melkonian C; Trudeau S; Daida YG; Schmidt MA; Gordon SC
Adv Ther; 2024 Feb; 41(2):744-758. PubMed ID: 38169058
[TBL] [Abstract][Full Text] [Related]
20. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan.
Liu CH; Liu CJ; Hung CC; Hsieh SM; Su TH; Sun HY; Tseng TC; Chen PJ; Chen DS; Kao JH
Liver Int; 2020 Apr; 40(4):758-768. PubMed ID: 31710759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]